New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
Executive Summary
Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.
You may also be interested in...
KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride
Since acquiring Nature's Bounty in 2010 and taking the publicly traded firm private, Carlyle could have been at the helm longer than executives at the private equity firm intended or expected, exceeding the five-year plan typical for similar investments.
Biopharma Quarterly Dealmaking Statistics, Q4 2016
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.